The Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at Medincell’s upcoming Annual General Meeting
Upon her election, 50% of Medincell’s Board will have been renewed since 2025, strengthening expertise in innovation, pharmaceutical development, governance, executive compensation and global health
Dr. Svanberg is expected to be named by the Board as Chair of Medincell’s Remuneration & Nomination Committee, subject to her election as a director by the shareholders
Dr. Elisabeth Svanberg MD, PhD, said: “Improving treatment adherence is one of the most important opportunities to improve healthcare today. Medincell’s long-acting technologies offer a compelling solution for patients worldwide, to meet this goal. As the Company enters a new phase of growth, I am honored to be proposed for election at the General Meeting. I look forward to working together with Medincells Directors and management, bringing my experience in pharmaceutical development, governance and global health to further support Medincell’s ambition to extend the impact of its innovations and create long-term value for patients and shareholders.”
Philippe Guy, Chairman of the Board of Medincell, said: “As Medincell enters a new phase of its development, we continue to strengthen a Board of Directors whose expertise reflects the Company’s international ambitions and strategic priorities. Elisabeth Svanberg’s exceptional experience in pharmaceutical development, corporate governance and the life sciences would be a valuable asset as Medincell pursues long-term value creation. Her appointment would be part of the Board renewal process initiated in 2025, a carefully managed evolution designed to bring new expertise and perspectives while preserving the continuity that remains essential to our success.”
Dr. Svanberg is an international life sciences executive with extensive experience across biotechnology and pharmaceuticals. A physician-scientist, board-certified surgeon, PhD and Associate Professor, she has held senior global leadership positions at Janssen Pharmaceutical, Bristol-Myers Squibb and Serono / Merck-Serono, with responsibilities spanning product development, medical affairs, portfolio strategy and regulatory interactions across major international markets.
She currently serves as Partner at Ventac Partners and holds several non-executive board roles in life sciences companies, including Chair of the Board of EPICS Therapeutics and Board Member of LEO Pharma A/S. She has also served on the boards of Galapagos NV, Amolyt SA, Egetis Therapeutics AB, Pharnext SA and Swedish Orphan Biovitrum AB. Dr. Svanberg also brings significant governance experience having served on remuneration and nomination committees of listed life sciences companies. Beyond her industry experience, she brings a strong global health perspective, including her board role in non-profit organizations such as Medicines for Malaria Venture.
Subject to shareholder approval of Dr. Svanberg appointment, Medincell’s Board of Directors would be composed as follows
| Board member | Board tenure* | Independence | Committees | ||||
| Audit & Finance | Remunaration & Nomination | Innovation & Strategy |
U.S. Growth Strategy | ESG | |||
| Philippe Guy, Chairman | Since 2010 | No** | Member | Member | Chair | ||
| Christophe Douat, CEO | Since 2024 | No** | Member | Member | |||
| Elisabeth Kogan | Since 2020 | Yes | Member | ||||
| Tone Kvåle | Since 2022 | Yes | Chair | ||||
| Dr. Pascal Touchon | Since 2025 | Yes | Chair | ||||
| Dr. Sharon Mates | Since 2025 | Yes | Chair | ||||
| Dr. Charles Kunsch | Since 2025 | Yes | Member | Member | |||
| Dr. Elisabeth Svanberg | Proposed 2026 | Yes | Expected Chair | ||||
* Board tenure includes, where applicable, prior service on Medincell’s Supervisory Board
** Philippe Guy is not considered independent due to his Board tenure, while Christophe Douat is not considered independent because of his executive responsibilities as Chief Executive Officer.
Future appointment of an employee shareholder representative to the Board of Directors
In addition, shareholders will be asked to approve the process for the future appointment of an employee shareholder representative to the Board of Directors, in accordance with applicable legal requirements regarding employee shareholder representation. Expected to take effect in 2027, this initiative reflects the growing importance of employee share ownership within Medincell and reinforces the Company’s commitment to long-term alignment and sustainable value creation for all shareholders.
Christophe Douat, CEO of Medincell, commented: “Employee share ownership has been part of Medincell’s DNA since our foundation. It has played an important role in attracting, retaining and motivating talented people while fostering strong alignment with all shareholders. The prospect of welcoming an employee shareholder representative to the Board marks an important milestone for the Company and reflects the growing contribution of our employees to Medincell’s long-term success.”
Departures from the Board of Directors
The Board also wishes to thank Virginie Lleu, who will step down from the Board at the close of the Annual General Meeting, for her long-standing contribution to Medincell’s governance and to the work of the Compensation Committee.
The Board also extends its thanks to Dr. Sabri Markabi for his significant contribution to Medincell’s governance. Dr. Markabi served as Vice-Chairman of the Board from 2018 to 2025 and has served as a Board observer over the past year. He will also step down from this role at the close of the Annual General Meeting.
About Medincell
Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.
These treatments combine active pharmaceutical ingredients with our proprietary BEPO® / BEPO® Star technologies, which enable controlled drug delivery at therapeutic levels for several days, weeks, or months following a subcutaneous or local injection of a small, fully bioresorbable depot.
Risperidone LAI was the first treatment based on BEPO® technology to receive FDA approval, initially for schizophrenia in April 2023, and subsequently for Bipolar I Disorder in October 2025. It is marketed in the United States by Teva under the brand name UZEDY®. Medincell’s risperidone LAI was also approved for schizophrenia in Canada and South Korea in 2025.
A New Drug Application (NDA) for Olanzapine LAI as a once-monthly treatment for schizophrenia in adults was submitted to the U.S. FDA in December 2025 by Medincell’s partner, Teva. The U.S. FDA accepted Teva’s NDA for Olanzapine LAI on February 20, 2026. A European Marketing Authorization Application (MAA) was also accepted by EMA in May 2026.
Medincell’s investigational pipeline includes numerous innovative therapeutic candidates in various stages of development, from formulation to Phase 3 clinical trials. We collaborate with leading pharmaceutical companies and foundations to advance global health through new treatment options.
Headquartered in Montpellier, France, Medincell employs over 150 people representing more than 27 nationalities.
UZEDY® is a trademark of Teva Pharmaceuticals. Medincell’s BEPO® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals.
Contact
David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@medincell.com / +33 (0)6 83 25 21 86
Grace Kim
Chief Strategy Officer, U.S. Finance
grace.kim@medincell.com / +1 (646) 991-4023
Nicolas Mérigeau / Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Louis-Victor Delouvrier / Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding Company’s expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company’s control and the Company’s financial capabilities.
These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as “objective”, “believe”, “anticipate”, “expect”, “foresee”, “aim”, “intend”, “may”, “anticipate”, “estimate”, “plan”, “project”, “will”, “may”, “probably”, “potential”, “should”, “could” and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the “AMF”) pursuant to its regulatory obligations, including the Company’s universal registration document, filed with the AMF on July 29, 2025, under number D. 25-0580 (the “Universal Registration Document”), as well as in the documents and reports to be published subsequently by the Company. In particular, readers’ attention is drawn to the section entitled “Facteurs de Risques” on page 30 et seq. 26 of the Registration Document.
Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company’s update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.
This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company’s shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.
